Engineered GAA Variants for pH Stability and Cellular Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for Pompe disease, such as recombinant acid alpha-glucosidase (GAA), are inadequate in providing sufficient enzyme activity, stability, and cellular uptake, leading to severe health complications and limited survival rates in affected individuals.
Innovation Solution
Engineered acid alpha-glucosidase (GAA) polypeptides optimized for increased expression, stability at neutral and acidic pH, and enhanced cellular uptake, along with improved activity in cell lysates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current enzyme replacement therapy using recombinant GAA is used, then Pompe disease treatment is provided, but insufficient enzyme activity and stability are achieved
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of GAA through site-directed mutagenesis, specifically changing pH-sensitive residues (e.g., E238Q, D248G) to improve stability at neutral pH while maintaining acidic pH activity. This resolves the contradiction by altering molecular parameters to achieve both reliability and ease of manufacture.
Solution Approach 2:
The patent applies local quality by making specific localized amino acid substitutions at key positions (e.g., N-terminal region, active site vicinity) rather than global modifications. This targeted approach improves enzyme stability and activity locally without compromising overall structure, resolving the contradiction between enzyme activity and stability.
2Ease of operation
If current recombinant GAA therapy is used, then treatment is provided, but cellular uptake is insufficient
Solution Approach 1:
The patent modifies cellular uptake parameters by engineering cell-penetrating properties into the GAA molecule through specific amino acid changes (e.g., adding positive charges, modifying surface properties). This enables the enzyme to cross cell membranes more efficiently, resolving the contradiction between ease of operation and therapeutic efficacy.
3Reliability
If current enzyme replacement therapy is used, then Pompe disease treatment is provided, but disease severity reduction is limited
Solution Approach 1:
The patent changes the functional parameters of GAA through amino acid engineering to enhance its therapeutic performance. By optimizing pH stability, cellular uptake, and enzymatic activity through specific mutations, the treatment achieves better disease severity reduction without increasing overall treatment complexity.
Data Source
AI summary
The present invention provides engineered acid alpha-glucosidase (GAA) polypeptides and compositions thereof. In some embodiments, the engineered GAA polypeptides have been optimized to provide increased expression, stability at neutral pH, and activity in cell lysates. The invention also provides methods for utilization of the compositions comprising the engineered GAA polypeptides for therapeutic and other purposes.